New insight into risk of ankylosing spondylitis

December 09, 2014

Scientists at the University of Southampton have discovered variations in an enzyme belonging to the immune system that leaves individuals susceptible to Ankylosing Spondylitis.

The variation in ERAP1 can be detected by genetic testing which, if available, could lead to people becoming aware of the risk of the condition earlier.

Ankylosing Spondylitis is a chronic inflammatory disease which mainly affects joints in the spine. In severe cases, it can eventually cause complete fusion and rigidity of the spine, called "Bamboo spine". It tends to first develop in teenagers and young adults with most cases first starting in people aged 20-30. Ankylosing Spondylitis is around three times more common in men than in women and there are around 200,000 people in the UK who have been diagnosed with the condition.

Although there is currently no cure, treatments and medications can reduce symptoms and pain, and very early diagnosis may even help to slow progression of the disease. It can take up to 10 years to make a diagnosis so a genetic test could revolutionise management of Ankylosing Spondylitis, the researchers say.

Professor Tim Elliott, who led the study with Dr Edd James at the University of Southampton, comments: "These natural variations in ERAP1, which are normally involved in T cell immunity, predispose individuals to Ankylosing Spondylitis. We have also discovered how variations in ERAP1 change its enzyme function - and this means that it might actually be a target for developing new drugs to treat Ankylosing Spondylitis.

During the study, published in the Proceedings of the National Academy of Sciences USA, the team sequenced DNA encoding the variations in ERAP1 found in patients with Ankylosing Spondylitis and controls. Results showed there were at least 13 different variants. Each of us has two copies of ERAP1 and the research showed that only certain pairwise combinations were found in patients but not controls.

The Southampton team, based at the Cancer Research UK Cancer Centre at Southampton General Hospital, was working on the importance of this enzyme in generating immunity to cancer when they made the discovery. They are now working to see if there is an association between ERAP1 variants and head and neck cancer.
-end-


University of Southampton

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.